Plain-English translation of NCT05748197 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a treatment called for people with acute myeloid leukemia (AML) that has stopped responding to standard chemotherapy. CAR T cells are immune cells that have been specially engineered in the laboratory to recognize and attack cancer cells. The study will first find the safest and most effective dose of these cells, then test that dose in a larger group of patients.
Acute myeloid leukemia can return or become resistant to standard chemotherapy, leaving patients with very few treatment options. This trial is exploring whether this new engineered immune cell therapy could offer hope to patients whose cancer has not responded to conventional treatments.
You likely qualify if…
You likely don't qualify if…
You will first receive chemotherapy to prepare your body for the treatment, either as an outpatient or inpatient. A few days later, you will be admitted to the hospital to receive an infusion of the engineered immune cells. The trial starts by testing the treatment at different dose levels in small groups to find the safest dose; once that is determined, more patients will receive the selected dose to see how well it works. You will be monitored closely during and after the treatment for safety and effectiveness.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States